CN109288945A - 一种治疗骨质增生外敷中药剂及其制备方法 - Google Patents
一种治疗骨质增生外敷中药剂及其制备方法 Download PDFInfo
- Publication number
- CN109288945A CN109288945A CN201811447879.9A CN201811447879A CN109288945A CN 109288945 A CN109288945 A CN 109288945A CN 201811447879 A CN201811447879 A CN 201811447879A CN 109288945 A CN109288945 A CN 109288945A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- decoction
- externally applied
- osteoproliferation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 title claims abstract description 57
- 239000003795 chemical substances by application Substances 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 241000746609 Piper hancei Species 0.000 claims abstract description 30
- 235000012907 honey Nutrition 0.000 claims abstract description 18
- 241001093951 Ailanthus altissima Species 0.000 claims abstract description 14
- 235000009847 Cucumis melo var cantalupensis Nutrition 0.000 claims abstract description 13
- 241000628997 Flos Species 0.000 claims abstract description 12
- 238000001914 filtration Methods 0.000 claims abstract description 11
- 235000015110 jellies Nutrition 0.000 claims abstract description 5
- 239000008274 jelly Substances 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000003292 glue Substances 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 239000000654 additive Substances 0.000 claims description 7
- 230000000996 additive effect Effects 0.000 claims description 7
- 238000009835 boiling Methods 0.000 claims description 7
- 239000006185 dispersion Substances 0.000 claims description 7
- 235000013312 flour Nutrition 0.000 claims description 7
- 238000005406 washing Methods 0.000 claims description 7
- 241000282994 Cervidae Species 0.000 claims description 3
- 108010010803 Gelatin Proteins 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 2
- 244000241257 Cucumis melo Species 0.000 claims 3
- 238000007654 immersion Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 21
- 208000002193 Pain Diseases 0.000 abstract description 11
- 244000064895 Cucumis melo subsp melo Species 0.000 abstract description 10
- 230000001225 therapeutic effect Effects 0.000 abstract description 7
- 230000001988 toxicity Effects 0.000 abstract description 3
- 231100000419 toxicity Toxicity 0.000 abstract description 3
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract 1
- 238000003756 stirring Methods 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 17
- 206010005963 Bone formation increased Diseases 0.000 description 14
- 238000012360 testing method Methods 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 8
- 238000012545 processing Methods 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 210000004872 soft tissue Anatomy 0.000 description 4
- 239000002689 soil Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 206010020718 hyperplasia Diseases 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 240000006409 Acacia auriculiformis Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000001741 anti-phlogistic effect Effects 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 230000004856 capillary permeability Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- IRHTZOCLLONTOC-UHFFFAOYSA-N hexacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCO IRHTZOCLLONTOC-UHFFFAOYSA-N 0.000 description 2
- LELOWRISYMNNSU-UHFFFAOYSA-N hydrogen cyanide Chemical compound N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 201000005630 leukorrhea Diseases 0.000 description 2
- VVOAZFWZEDHOOU-UHFFFAOYSA-N magnolol Chemical compound OC1=CC=C(CC=C)C=C1C1=CC(CC=C)=CC=C1O VVOAZFWZEDHOOU-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- NEPMMBQHELYZIW-YMTXFHFDSA-N sakuranin Chemical compound O([C@@H](CC(=O)C1=2)C=3C=CC(O)=CC=3)C1=CC(OC)=CC=2O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NEPMMBQHELYZIW-YMTXFHFDSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229910052624 sepiolite Inorganic materials 0.000 description 2
- 235000019355 sepiolite Nutrition 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- 206010046901 vaginal discharge Diseases 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 102000030523 Catechol oxidase Human genes 0.000 description 1
- 108010031396 Catechol oxidase Proteins 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 235000002722 Dioscorea batatas Nutrition 0.000 description 1
- 235000006536 Dioscorea esculenta Nutrition 0.000 description 1
- 240000001811 Dioscorea oppositifolia Species 0.000 description 1
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 240000001307 Myosotis scorpioides Species 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 239000004113 Sepiolite Substances 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- DWCSNWXARWMZTG-UHFFFAOYSA-N Trigonegenin A Natural products CC1C(C2(CCC3C4(C)CCC(O)C=C4CCC3C2C2)C)C2OC11CCC(C)CO1 DWCSNWXARWMZTG-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 238000005899 aromatization reaction Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- WQLVFSAGQJTQCK-VKROHFNGSA-N diosgenin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)CC4=CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 WQLVFSAGQJTQCK-VKROHFNGSA-N 0.000 description 1
- WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 238000001827 electrotherapy Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 239000010436 fluorite Substances 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 239000011133 lead Substances 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- ZADYMNAVLSWLEQ-UHFFFAOYSA-N magnesium;oxygen(2-);silicon(4+) Chemical compound [O-2].[O-2].[O-2].[Mg+2].[Si+4] ZADYMNAVLSWLEQ-UHFFFAOYSA-N 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 239000003516 soil conditioner Substances 0.000 description 1
- 239000004016 soil organic matter Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
- A61K36/575—Magnolia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种治疗骨质增生外敷中药剂及其制备方法,属于中药技术领域。该外敷中药剂,为稠膏状的中药剂,包括以下按照重量份计的组分:甜瓜子10‑18份、石楠叶20‑35份、花蕊石5‑10份、广山药5‑10份、椿皮7‑12份、厚朴花3‑9份。将上述原料捣碎、分散、浸泡、煮沸、过滤得到药汁,然后再将药汁加入胶剂和蜂蜜继续煎煮、搅拌便可制得稠膏状的中药剂。本发明的配方新颖,制得的外敷中药剂对骨质增生具有很明显的治疗效果,且还拥有无毒无副作用、疗效快以及外敷时可消除疼痛感等特点。
Description
技术领域
本发明涉及中药技术领域,具体是一种治疗骨质增生外敷中药剂及其制备方法。
背景技术
骨质增生,又称增生性骨关节炎,是人体衰老的一种正常退化现象,包括有颈椎骨质增生、腰椎骨质增生和膝关节骨质增生等。人到了一定年龄之后,由于长时间活动、高负荷的压力下,关节边缘会形成骨刺,而骨刺会对软组织产生机械性的刺激,导致软组织会受到损伤、出血以及肿胀,从而引起一系列症状。
目前,现有技术中有采用西药、口服中药、电疗等方法治疗骨质增生,但是都存在治疗效果不明显、疗程长或者副作用明显等弊端,故还是难以推广应用于治疗骨质增生。
发明内容
本发明的目的在于提供一种疗效快、效果明显的用于治疗骨质增生的外敷中药剂及其制备方法,以解决上述背景技术中提出的问题。
为实现上述目的,本发明提供如下技术方案:
一种治疗骨质增生外敷中药剂,为稠膏状的中药剂,包括以下按照重量份计的组分:甜瓜子10-18份、石楠叶20-35份、花蕊石5-10份、广山药5-10份、椿皮7-12份、厚朴花3-9份。
作为本发明进一步的方案,一种治疗骨质增生外敷中药剂,包括以下按照重量份计的组分:甜瓜子12-16份、石楠叶25-30份、花蕊石7-9份、广山药7-9份、椿皮8-10份、厚朴花5-7份。
作为本发明再进一步的方案,一种治疗骨质增生外敷中药剂,包括以下按照重量份计的组分:甜瓜子15份、石楠叶27份、花蕊石8份、广山药8份、椿皮9份、厚朴花6份。
上述治疗骨质增生外敷中药剂的制备方法,包括以下步骤:
(1)先将花蕊石和广山药研磨成粉,然后将得到的花蕊石粉和广山药粉按照上述重量份与其他组分混合在一起并捣碎;
(2)将捣碎后的药材加入无水乙醇进行搅拌分散,然后过滤掉无水乙醇,经水洗后,再放置于冷水中浸泡1-3天;
(3)浸泡后,用大火先对其加热煮沸,然后用小火维持沸腾的状态,持续1-3小时后,过滤得到药汁和药渣;
(4)将药渣加水继续煮沸,重复步骤(3),得到药汁和药渣;
(5)将步骤(3)和步骤(4)得到的药汁混合在一起,静置沉淀8-12小时后,过滤得到较为纯净的药汁;
(6)往步骤(5)的药汁中加入胶剂和蜂蜜,然后用小火煎煮,将水分蒸发,并不断搅拌,即可制得稠膏状的中药剂。
作为本发明再进一步的方案,所述步骤(5)的过滤步骤是采用经过消毒处理的多层纱布进行过滤。
作为本发明再进一步的方案,所述步骤(6)中的胶剂为阿胶、龟板胶和鹿角胶中的一种或者多种。
作为本发明再进一步的方案,所述步骤(6)中的蜂蜜的添加量为药汁总重量的2%-8%。
另外,本发明所选用的各药材的功效如下:
甜瓜子:性寒,味甘;含蛋白质、脂肪、维生素C、胡萝卜素和多种氨基酸等营养物质,可驱虫、抑菌,具有活血、清肺、润肠、化瘀、排脓、疗伤止痛功效,用治肺热咳嗽、便秘、肺痈、肠痈、跌打损伤、筋骨折伤。
石楠叶:性平,味辛、苦;含鞣质、樱花苷、山梨醇、正烷烃、苯甲醛、氢氰酸等成分,具有祛风湿、止痒、强筋骨、益肝肾的功效,主治风湿痹痛、头风头痛、风疹、脚膝痿弱、肾虚腰痛。
花蕊石:性平,味酸、涩;主含碳酸钙,尚含水硅酸镁和少量铁、铝及微量锌、锰、铜、钴、镍、铬、铅等20多种元素,具有化瘀止血的功效,用治咯血、吐血、外伤出血、跌扑伤痛。
广山药:性平,味甘;含薯蓣皂苷元、多巴胺、盐酸山药碱、多酚氧化酶、尿囊素和止权素等,能起到降血糖、调节免疫功能、抗氧化、延缓衰老的作用,具有健脾养胃、生津益肺、补肾涩精的功效,主治脾虚泄泻、肺虚喘咳、糖尿病、体虚白带。
椿皮:性寒,味苦、涩;含臭椿内酯、脂肪酸、植物甾醇、转化糖、蜡醇、鞣质、臭椿苦酮、苦木素等成分,能起到抗癌和抗阿米巴原虫等作用,具有清热燥湿、收涩止带、止泻、止血的功效,用治赤白带下、湿热泻痢、久泻久痢、便血、崩漏。
厚朴花:性温,味苦;主要有厚朴酚和樟脑等成分,能起降血压的作用,具有芳香化湿,理气宽中的功效,用治湿阻气滞之脘腹胀满、疼痛等。
与现有技术相比,本发明的有益效果是:
本发明的配方新颖,通过加入花蕊石组分,并在与广山药等组分的复配作用下,以及在制备中药剂的过程中添加蜂蜜,可以制得具有补血活血、清热解毒、祛风除湿、强筋止痛等功效的外敷中药剂,对骨质增生具有很明显的治疗效果,尤其是颈椎骨质增生和腰椎骨质增生,且还拥有无毒无副作用、疗程短、疗效快以及外敷时可消除疼痛感等特点。
具体实施方式
下面结合具体实施方式对本发明的技术方案作进一步详细地说明。
实施例1
一种治疗骨质增生外敷中药剂,为稠膏状的中药剂,包括以下按照重量份计的组分:甜瓜子10份、石楠叶20份、花蕊石5份、广山药5份、椿皮7份、厚朴花3份。
上述治疗骨质增生外敷中药剂的制备方法,包括以下步骤:
(1)先将花蕊石和广山药研磨成粉,然后将得到的花蕊石粉和广山药粉按照上述重量份与其他组分混合在一起并捣碎;
(2)将捣碎后的药材加入无水乙醇进行搅拌分散,然后过滤掉无水乙醇,经水洗后,再放置于冷水中浸泡1天;
(3)浸泡后,用大火先对其加热煮沸,然后用小火维持沸腾的状态,持续1小时后,过滤得到药汁和药渣;
(4)将药渣加水继续煮沸,重复步骤(3),得到药汁和药渣;
(5)将步骤(3)和步骤(4)得到的药汁混合在一起,静置沉淀8小时后,用经过消毒处理的多层纱布进行过滤得到较为纯净的药汁;
(6)往步骤(5)的药汁中加入适量的鹿角胶和蜂蜜,其中蜂蜜的添加量为药汁总重量的2%%,然后用小火煎煮,将水分蒸发,并不断搅拌,即可制得稠膏状的中药剂。
实施例2
一种治疗骨质增生外敷中药剂,为稠膏状的中药剂,包括以下按照重量份计的组分:甜瓜子18份、石楠叶35份、花蕊石10份、广山药10份、椿皮12份、厚朴花9份。
上述治疗骨质增生外敷中药剂的制备方法,包括以下步骤:
(1)先将花蕊石和广山药研磨成粉,然后将得到的花蕊石粉和广山药粉按照上述重量份与其他组分混合在一起并捣碎;
(2)将捣碎后的药材加入无水乙醇进行搅拌分散,然后过滤掉无水乙醇,经水洗后,再放置于冷水中浸泡3天;
(3)浸泡后,用大火先对其加热煮沸,然后用小火维持沸腾的状态,持续3小时后,过滤得到药汁和药渣;
(4)将药渣加水继续煮沸,重复步骤(3),得到药汁和药渣;
(5)将步骤(3)和步骤(4)得到的药汁混合在一起,静置沉淀12小时后,用经过消毒处理的多层纱布进行过滤得到较为纯净的药汁;
(6)往步骤(5)的药汁中加入适量的阿胶和蜂蜜,其中蜂蜜的添加量为药汁总重量的8%,然后用小火煎煮,将水分蒸发,并不断搅拌,即可制得稠膏状的中药剂。
实施例3
一种治疗骨质增生外敷中药剂,为稠膏状的中药剂,包括以下按照重量份计的组分:甜瓜子12份、石楠叶25份、花蕊石7份、广山药7份、椿皮8份、厚朴花5份。
上述治疗骨质增生外敷中药剂的制备方法,包括以下步骤:
(1)先将花蕊石和广山药研磨成粉,然后将得到的花蕊石粉和广山药粉按照上述重量份与其他组分混合在一起并捣碎;
(2)将捣碎后的药材加入无水乙醇进行搅拌分散,然后过滤掉无水乙醇,经水洗后,再放置于冷水中浸泡2天;
(3)浸泡后,用大火先对其加热煮沸,然后用小火维持沸腾的状态,持续2小时后,过滤得到药汁和药渣;
(4)将药渣加水继续煮沸,重复步骤(3),得到药汁和药渣;
(5)将步骤(3)和步骤(4)得到的药汁混合在一起,静置沉淀11小时后,用经过消毒处理的多层纱布进行过滤得到较为纯净的药汁;
(6)往步骤(5)的药汁中加入适量的龟板胶和蜂蜜,其中蜂蜜的添加量为药汁总重量的6%,然后用小火煎煮,将水分蒸发,并不断搅拌,即可制得稠膏状的中药剂。
实施例4
一种治疗骨质增生外敷中药剂,为稠膏状的中药剂,包括以下按照重量份计的组分:甜瓜子16份、石楠叶30份、花蕊石9份、广山药9份、椿皮10份、厚朴花7份。
上述治疗骨质增生外敷中药剂的制备方法,包括以下步骤:
(1)先将花蕊石和广山药研磨成粉,然后将得到的花蕊石粉和广山药粉按照上述重量份与其他组分混合在一起并捣碎;
(2)将捣碎后的药材加入无水乙醇进行搅拌分散,然后过滤掉无水乙醇,经水洗后,再放置于冷水中浸泡2天;
(3)浸泡后,用大火先对其加热煮沸,然后用小火维持沸腾的状态,持续2小时后,过滤得到药汁和药渣;
(4)将药渣加水继续煮沸,重复步骤(3),得到药汁和药渣;
(5)将步骤(3)和步骤(4)得到的药汁混合在一起,静置沉淀11小时后,用经过消毒处理的多层纱布进行过滤得到较为纯净的药汁;
(6)往步骤(5)的药汁中加入适量的龟板胶和蜂蜜,其中蜂蜜的添加量为药汁总重量的6%,然后用小火煎煮,将水分蒸发,并不断搅拌,即可制得稠膏状的中药剂。
实施例5
一种治疗骨质增生外敷中药剂,为稠膏状的中药剂,包括以下按照重量份计的组分:甜瓜子15份、石楠叶27份、花蕊石8份、广山药8份、椿皮9份、厚朴花6份。
上述治疗骨质增生外敷中药剂的制备方法,包括以下步骤:
(1)先将花蕊石和广山药研磨成粉,然后将得到的花蕊石粉和广山药粉按照上述重量份与其他组分混合在一起并捣碎;
(2)将捣碎后的药材加入无水乙醇进行搅拌分散,然后过滤掉无水乙醇,经水洗后,再放置于冷水中浸泡2天;
(3)浸泡后,用大火先对其加热煮沸,然后用小火维持沸腾的状态,持续2小时后,过滤得到药汁和药渣;
(4)将药渣加水继续煮沸,重复步骤(3),得到药汁和药渣;
(5)将步骤(3)和步骤(4)得到的药汁混合在一起,静置沉淀11小时后,用经过消毒处理的多层纱布进行过滤得到较为纯净的药汁;
(6)往步骤(5)的药汁中加入适量的龟板胶和蜂蜜,其中蜂蜜的添加量为药汁总重量的6%,然后用小火煎煮,将水分蒸发,并不断搅拌,即可制得稠膏状的中药剂。
对比例1
除不含有花蕊石组分,其余组分、含量及其制备方法和实施例5相同。
对比例2
除不含有广山药组分,其余组分、含量及其制备方法和实施例5相同。
对比例3
除制备方法中的步骤(6)中不添加蜂蜜,其余组分、含量及其制备方法和实施例5相同。
动物实验:
先取60只实验小鼠,并用二甲苯涂抹在实验小鼠的右耳耳廓后面,由于受到二甲苯的刺激作用,小鼠耳局部的毛细血管会充血,发生水肿状况;然后将涂抹过二甲苯的50只实验小鼠平均分成6组,分别用实施例5、对比例1-3、对照组1和空白组的药物进行给药。其中对照组1为阿司匹林,采用口服的方式给药,一天1次,一次5ml;空白组为生理盐水,空白组、实施例5、对比例1-3采用外敷的方式给药,一天1次,一次5g。给药3天后,对实验小鼠的耳廓肿胀度(右耳重量减去左耳片重即为肿胀度)、毛细血管通透性(耳廓染料渗出液OD值以及耳廓染料渗出的抑制率)进行检测,检测结果(实施例组、对比例组、对照组和空白组比较,其差异具有非常显著意义,P<0.01)见下表1:
经过连续3天的给药时间,小鼠无死亡现象,也没有其他异常现象。另外,从上表1的实验结果可以看到,本发明实施例5制得外敷药物可以消肿,具有较强的抑制炎症的作用,以及对二甲苯所致炎症造成的毛细血管通透性增加和染料渗出具有很强的抑制作用,其效果与阿司匹林相接近。
临床试验:
将上述实施例5和对比例1-3制得的外敷中药剂,敷在骨质增生患者的患处,每日一次,一次10g,5天一个疗程;
对照组2:患者口服骨刺消痛液,一次15ml,一日2次,5天一个疗程。
疗效评定标准:
1、治愈:临床症状基本消失,无疼痛感,局部活动也无明显受限,可恢复正常工作。
2、有效:临床症状明显改善,受寒、剧烈运动、过度劳累后会出现症状,但跟之前比有所减轻。
3、无效:用药2个疗程后,临床症状基本没有改善,仍然会有疼痛感。
试验结果:
一共150例颈椎骨质增生患者和150例腰椎骨质增生,年龄最小的40岁,最大的75岁,平均年龄50岁,另外,病程最短的2年,最长的7年。其中,150例颈椎骨质增生患者的治疗情况(治疗2个疗程)如下表2:
表2
测试项目 | 病例数 | 无效例 | 有效例 | 治愈例 | 总有效率(%) |
对照组2 | 30 | 7 | 18 | 5 | 76.7 |
实施例5 | 30 | 0 | 3 | 27 | 100.0 |
对比例1 | 30 | 12 | 15 | 3 | 60.0 |
对比例2 | 30 | 14 | 14 | 2 | 53.3 |
对比例3 | 30 | 6 | 14 | 10 | 80.0 |
另外,150例腰椎骨质增生患者的治疗情况(治疗2个疗程)如下表3:
表3
测试项目 | 病例数 | 无效例 | 有效例 | 治愈例 | 总有效率(%) |
对照组2 | 30 | 9 | 19 | 2 | 70.0 |
实施例5 | 30 | 0 | 4 | 26 | 100.0 |
对比例1 | 30 | 13 | 15 | 2 | 56.7 |
对比例2 | 30 | 15 | 14 | 1 | 50.0 |
对比例3 | 30 | 7 | 14 | 9 | 76.7 |
由上表2、表3的试验结果可以看出,本发明制得的外敷中药剂用于颈椎骨质增生患者和腰椎骨质增生患者均有明显的治疗效果,治疗2个疗程,总有效率均可达到100%;相比于口服骨刺消痛液,无毒无副作用,且拥有更有效的治疗效果。
从表2、表3中对比例1-2与实施例5的试验结果可以看出,本发明通过加入花蕊石组分,并在与广山药等组分的复配作用下,制得的外敷中药剂对颈椎骨质增生和腰椎骨质增生均有很明显的治疗效果,取得预料不到的技术效果。
另外,从表2、表3中对比例3与实施例5的试验结果可以看出,本发明通过在制备中药剂的过程中添加蜂蜜,可以提高对颈椎骨质增生和腰椎骨质增生的治疗效果。
从对比例1和实施例5的测试结果可以看出,本发明通过加入经过季铵盐型双子表面活性剂改性处理的海泡石,可以显著降低土壤的PH值、盐含量、CO3 2-和HCO3 -含量以及提升对土壤碱化度的改良效果和提升土壤的有机质含量。
另外,从对比例2-3和实施例5的测试结果可以看出,本发明通过加入萤石粉,并在与改性海泡石和水杨酸等组分的复配作用上,可以制得对盐碱化土壤具有高效改良效果,并且可以提升土壤有机质含量的土壤改良剂。
典型病例:
1、高XX,男,51岁,颈椎骨质增生已经5年,具有头疼、颈背疼、上肢无力等病状,以及偶尔出现会手指发麻和头晕,使用本发明的外敷中药剂2个疗程后,效果明显,疼痛感基本消失了,也不会出现手指发麻和头晕等病状,可正常活动和工作。
2、林XX,男,62岁,腰椎骨质增生已经7年,具有腰椎及腰部软组织酸痛、胀痛、僵硬与疲乏感等病状,而且弯腰受限,使用本发明的外敷中药剂2个疗程后,效果明显,腰椎及腰部软组织不再疼痛,也可正常进行弯腰。
对于本领域技术人员而言,显然本发明不限于上述示范性实施例的细节,而且在不背离本发明的精神或基本特征的情况下,能够以其他的具体形式实现本发明。因此,无论从哪一点来看,均应将实施例看作是示范性的,而且是非限制性的,本发明的范围由所附权利要求而不是上述说明限定,因此旨在将落在权利要求的等同要件的含义和范围内的所有变化囊括在本发明内。
此外,应当理解,虽然本说明书按照实施方式加以描述,但并非每个实施方式仅包含一个独立的技术方案,说明书的这种叙述方式仅仅是为清楚起见,本领域技术人员应当将说明书作为一个整体,各实施例中的技术方案也可以经适当组合,形成本领域技术人员可以理解的其他实施方式。
Claims (7)
1.一种治疗骨质增生外敷中药剂,为稠膏状的中药剂,其特征在于,包括以下按照重量份计的组分:甜瓜子10-18份、石楠叶20-35份、花蕊石5-10份、广山药5-10份、椿皮7-12份、厚朴花3-9份。
2.根据权利要求1所述的一种治疗骨质增生外敷中药剂,其特征在于,包括以下按照重量份计的组分:甜瓜子12-16份、石楠叶25-30份、花蕊石7-9份、广山药7-9份、椿皮8-10份、厚朴花5-7份。
3.根据权利要求1所述的一种治疗骨质增生外敷中药剂,其特征在于,包括以下按照重量份计的组分:甜瓜子15份、石楠叶27份、花蕊石8份、广山药8份、椿皮9份、厚朴花6份。
4.一种如权利要求1-3任一项所述的治疗骨质增生外敷中药剂的制备方法,其特征在于,包括以下步骤:
先将花蕊石和广山药研磨成粉,然后将得到的花蕊石粉和广山药粉按照上述重量份与其他组分混合在一起并捣碎;
将捣碎后的药材加入无水乙醇进行搅拌分散,然后过滤掉无水乙醇,经水洗后,再放置于冷水中浸泡1-3天;
浸泡后,用大火先对其加热煮沸,然后用小火维持沸腾的状态,持续1-3小时后,过滤得到药汁和药渣;
将药渣加水继续煮沸,重复步骤(3),得到药汁和药渣;
将步骤(3)和步骤(4)得到的药汁混合在一起,静置沉淀8-12小时后,过滤得到较为纯净的药汁;
往步骤(5)的药汁中加入胶剂和蜂蜜,然后用小火煎煮,将水分蒸发,并不断搅拌,即可制得稠膏状的中药剂。
5.根据权利要求4所述的一种治疗骨质增生外敷中药剂的制备方法,其特征在于,所述步骤(5)的过滤步骤是采用经过消毒处理的多层纱布进行过滤。
6.根据权利要求4所述的一种治疗骨质增生外敷中药剂的制备方法,其特征在于,所述步骤(6)中的胶剂为阿胶、龟板胶和鹿角胶中的一种或者多种。
7.根据权利要求4所述的一种治疗骨质增生外敷中药剂的制备方法,其特征在于,所述步骤(6)中的蜂蜜的添加量为药汁总重量的2%-8%。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811447879.9A CN109288945A (zh) | 2018-11-29 | 2018-11-29 | 一种治疗骨质增生外敷中药剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811447879.9A CN109288945A (zh) | 2018-11-29 | 2018-11-29 | 一种治疗骨质增生外敷中药剂及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109288945A true CN109288945A (zh) | 2019-02-01 |
Family
ID=65141772
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811447879.9A Withdrawn CN109288945A (zh) | 2018-11-29 | 2018-11-29 | 一种治疗骨质增生外敷中药剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109288945A (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104095973A (zh) * | 2014-07-30 | 2014-10-15 | 吴英娥 | 用于治疗骨质增生的外用中药组合物及其制备 |
CN105434795A (zh) * | 2015-12-08 | 2016-03-30 | 暨南大学 | 一种含有艾叶的外敷治疗骨质增生的中药制剂 |
-
2018
- 2018-11-29 CN CN201811447879.9A patent/CN109288945A/zh not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104095973A (zh) * | 2014-07-30 | 2014-10-15 | 吴英娥 | 用于治疗骨质增生的外用中药组合物及其制备 |
CN105434795A (zh) * | 2015-12-08 | 2016-03-30 | 暨南大学 | 一种含有艾叶的外敷治疗骨质增生的中药制剂 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108310339A (zh) | 一种排毒祛湿养生足贴 | |
CN105166544A (zh) | 一种猪配合饲料及其制备方法 | |
CN104206916A (zh) | 一种用于治疗鲫鱼鱼怪病的功能性饲料及其制备方法 | |
CN103816292A (zh) | 一种中药足浴粉及其制备方法 | |
KR101102831B1 (ko) | 천연약재를 이용한 기능성 건강식품 제조방법 및 상기 제조방법에 의해 제조된 기능성 건강식품 | |
CN105056159A (zh) | 一种治疗猪寄生虫病的药物及其制备方法 | |
CN105031408B (zh) | 一种改善痛风的组合物 | |
CN106389881A (zh) | 一种活血散瘀膏 | |
CN105832619A (zh) | 杀菌除臭足浴盐及制备方法 | |
CN105343865A (zh) | 一种治疗神经性呕吐的药物及其制备方法 | |
CN104605372A (zh) | 一种基于恶性肿瘤放疗患者的营养药膳及制备方法 | |
CN109288945A (zh) | 一种治疗骨质增生外敷中药剂及其制备方法 | |
CN107913346A (zh) | 一种祛除鳞屑的外用药物搽剂及其制备方法和应用 | |
CN102961633B (zh) | 一种用于治疗产后风湿病的制剂 | |
CN110090285A (zh) | 一种治疗坐骨神经痛的膏药及其制备方法 | |
CN109010778A (zh) | 一种祛湿中药组合物及其制备方法 | |
KR101290190B1 (ko) | 오디와 검은 참깨를 포함한 건강 보조식품 조성물 및 그 제조방법 | |
KR20180130894A (ko) | 쌍화차를 이용한 한방삼겹살 제조방법 | |
CN106619852A (zh) | 一种温经敌寒、疏散腠理中药足浴养生保健方剂 | |
CN104971157A (zh) | 一种治疗脚气的外搽粉及制法 | |
CN104645244A (zh) | 一种治疗动脉硬化症的中药组合物 | |
CN104435273B (zh) | 一种治疗烧伤烫伤的中药及其制备方法 | |
KR20030075250A (ko) | 생기환골드 | |
CN104189313A (zh) | 一种用于治疗鲫鱼鱼怪病的药物组合物及其制备方法 | |
CN104383057A (zh) | 主治跌打损伤膏及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20190201 |